LURBINECTEDIN
Lurbinectedin inhibits RNA polymerase II, inducing apoptosis in oncogene‑driven tumors, used for small‑cell lung cancer. Side effects include myelosuppression, fatigue, nausea, and elevated liver enzymes.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP Manufacturers
Let us handle your sourcing / supply activities. For years we have sourced specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
We are committed to supplying high-quality GMP products with logistics accoring to GDP regulations
Product Description
Mechanism of Action
LURBINECTEDIN (ID 30221) exhibits a broad-spectrum mechanistic footprint involving catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial energy‑network recalibration, membrane‑potential stabilization/destabilization, ion‑flux redistribution, cytoskeletal‑architecture remodelling, redox‑equilibrium disruption and transcription‑factor network reprogramming. Its physicochemical and conformational architecture supports interaction with catalytic microdomains, allosteric regulators, transmembrane helices, hydrophobic receptor pockets, nucleotide‑binding centres, redox‑buffer modules and multi‑protein scaffolds—producing wide‑band influence across metabolic, genomic, structural and electrophysiological systems.
LURBINECTEDIN may alter phosphorylation topology across ERK/MAPK/JNK/p38 and PI3K–AKT signalling chains, shift G‑protein signalling geometry, reconfigure Ca²⁺ microdomain amplitude/propagation, reshape IP₃/DAG cascade architecture, and recalibrate cAMP‑PKA signalling thresholds. Mitochondrially, it can rebalance ETC‑complex activation, modulate ATP/ADP turnover kinetics, shift ROS‑leakage thresholds, alter membrane‑potential polarity and propagate ER–mitochondrial cross‑stress signals. These features make it highly relevant for deep mechanistic and translational research.
Advanced Research Applications
- Kinome‑scale interference modelling and catalytic‑cascade rebuilding
- Ultra‑resolution ligand docking and conformational‑transition prediction algorithms
- UPR/ER‑stress, mitochondrial‑stress, autophagy and mitophagy axis modelling
- Full‑stack multi‑omics system reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
- Cytoskeletal tension‑mapping, actin/tubulin turnover modelling and force‑distribution analytics
- Cell‑fate modelling across apoptosis, necroptosis, pyroptosis, ferroptosis and parthanatos
- Advanced AI‑driven SAR/QSAR predictive molecular‑performance mapping
Toxicodynamics & Hazard Spectrum
- Accelerated ROS accumulation and antioxidant‑buffer collapse
- Mitochondrial fragmentation, ETC shutdown or hyper‑leakage states
- Severe Na⁺/K⁺/Ca²⁺ ion‑transport dysregulation
- Cytoskeletal depolymerisation, microtubule instability and global mechanical failure
- Membrane‑integrity disruption, bilayer thinning and permeability shifts
- NF‑κB / STAT / IRF inflammatory‑axis hyperactivation
- Multi‑axis programmed cell‑death initiation
- Epigenetic drift across methylation/acetylation landscapes
For expert laboratory research only — not intended for biological or therapeutic exposure.
Datasheet
| Molecular Formula | C32H29N3O5S2 |
|---|---|
| Molecular Weight | 784.9 g/mol |
| CAS Number | 497871-47-3 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Lurbinectedin; 497871-47-3; PM01183; Tryptamicidin; Zepzelca |
| IUPAC/Chemical Name | [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate |
| InChl Key | YDDMIZRDDREKEP-HWTBNCOESA-N |
| InChl Code | InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.


